Skip to main content
< Back
About
About the conference
App
Organisers & Partners
Latest updates
Press room
Registration
Venue 22
About the venue
Rooms
Call for abstracts
Programme 22
Tracks 22
Speakers 22
Side events 22
Subscribe
days
hours
minutes
seconds
Previous track
Open track
In programme
69 sessions
335 presentations
View the programme
About
Sessions
Wednesday, 23 November
10:50
Advances in toxicology
10:50
to
12:20
Central square 2 (C2)
Oral presentation session
COVID-19 implications for services and responses
10:50
to
12:20
Central square 3 (C3)
Oral presentation session
Emerging changes in Europe's cannabis situation: policy preparedness and responses to a dynamic situation
10:50
to
12:20
Knowledge market 4 (K4)
Structured session
Getting your addiction research published
10:50
to
12:20
Central square 4 (C4)
Workshop
Improving knowledge, taking action
10:50
to
12:20
Networking zone 1 (N1)
e-poster guided tour
Prescription opioids and overdose deaths
10:50
to
12:20
Knowledge market 1 (K1)
Structured session
Reaching out
10:50
to
12:20
Networking zone 4 (N4)
Short communication session
13:20
Assessing the impact of laws and policies regulating illicit drugs on health and society: some insights
13:20
to
14:50
Knowledge market 4 (K4)
Structured session
Cannabis
13:20
to
14:50
Networking zone 2 (N2)
e-poster guided tour
Drug problems, perspectives and patterns of use
13:20
to
14:50
Networking zone 4 (N4)
Short communication session
e-/m-health interventions for substance use disorders
13:20
to
14:50
Central square 3 (C3)
Oral presentation session
Global digital addiction interventions: adaptations to target audiences and effectiveness
13:20
to
14:50
Insights zone 2 (I2)
Structured session
Prevention and control of infectious diseases among people who inject drugs: New evidence within the updated guidance from the ECDC and the EMCDDA
13:20
to
14:50
Networking zone 3 (N3)
Structured session
Special at-risk populations and need for diversified interventions to prevent overdoses: insights from the US and Europe, on fentanyl, suicidal overdoses and deaths among teen-agers
13:20
to
14:50
Central square 4 (C4)
Structured session
The future for Digital Addictions Services. An update from the DigitAS-DADE Project
13:20
to
14:50
Central square 2 (C2)
Structured session
15:00
Drug Early Warning Systems – the key to preparedness and response to new psychoactive substances
15:00
to
16:30
Central square 2 (C2)
Structured session
Estimating harm
15:00
to
16:30
Central square 3 (C3)
Oral presentation session
Estimating prevalence
15:00
to
16:30
Knowledge market 4 (K4)
Oral presentation session
Scenario Engagement Workshop
15:00
to
16:30
Central square 4 (C4)
Workshop
Towards endemicity: A global perspective of the many variants of drug consumption rooms and service models in operation
15:00
to
16:30
Insights zone 3 (I3)
Structured session
16:50
Driving under the influence of cannabis (DUIC)
16:50
to
18:20
Insights zone 3 (I3)
Structured session
EU4MD Treatment facility survey
16:50
to
18:20
Networking zone 2 (N2)
Oral presentation session
Focusing on gender issues
16:50
to
18:20
Central square 3 (C3)
Oral presentation session
Improving knowledge, protecting health
16:50
to
18:20
Networking zone 3 (N3)
Short communication session
Treatment options for drug users in prisons in Central Asia and Germany
16:50
to
18:20
Networking zone 1 (N1)
Structured session
Why we need evidence-based approaches for the universal measurement of cannabis: rationale and implications for public health, treatment and research
16:50
to
18:20
Main stage
Structured session
Thursday, 24 November
09:00
Contemporary Issues
09:00
to
10:30
Central square 2 (C2)
Oral presentation session
The Spanish Network on Research on Primary Attention on Addiction (RIAPAd): a new multilevel integrated model of responsible research on Addiction Disorders
09:00
to
10:30
Knowledge market 4 (K4)
Structured session
10:50
From Harm to Risk Reduction: OKANA’s 360o approach in Athens
10:50
to
12:20
Knowledge market 4 (K4)
Structured session
Neurology and neuropsychology
10:50
to
12:20
Central square 3 (C3)
Oral presentation session
Practitioners informing practice
10:50
to
12:20
Knowledge market 3 (K3)
Oral presentation session
Studying illegal drugs in socially embedded markets
10:50
to
12:20
Central square 2 (C2)
Structured session
Successful systemic management for addiction challenges and all its side effects
10:50
to
12:20
Central square 4 (C4)
Structured session
Understanding women's drug use, responses and recovery
10:50
to
12:20
Networking zone 4 (N4)
Short communication session
13:20
Cannabis and tobacco co-use: A ‘joint’ challenge for research and practice
13:20
to
14:50
Knowledge market 1 (K1)
Structured session
Drug checking in supervised drug consumption room: rationale, methods and results
13:20
to
14:50
Central square 4 (C4)
Structured session
Methods and Problems with Estimating Prevalence of People Who Inject Drugs, studies and debate on how to get better and more consistent estimates in Europe and Rest of the World
13:20
to
14:50
Central square 2 (C2)
Structured session
Smoking and e-cigarettes
13:20
to
14:50
Central square 3 (C3)
Oral presentation session
Uppers, downers and psychedelics
13:20
to
14:50
Networking zone 3 (N3)
Short communication session
15:00
A global symposium on the renaissance and promise of psychedelics for mental and substance use disorder treatment
15:00
to
16:30
Main stage
Structured session
Client-centered approaches
15:00
to
16:30
Central square 3 (C3)
Oral presentation session
Drug and alcohol treatment
15:00
to
16:30
Networking zone 1 (N1)
e-poster guided tour
Implementing Methamphetamine Prevention Strategies into Action (IMPRESA)
15:00
to
16:30
Knowledge market 4 (K4)
Structured session
Insights into acute recreational drug and new psychoactive substance toxicity – an update from the Euro-DEN Plus Project
15:00
to
16:30
Central square 2 (C2)
Structured session
16:50
Informing and delivering treatment
16:50
to
18:20
Networking zone 3 (N3)
Short communication session
Insights from treatment I
16:50
to
18:20
Central square 3 (C3)
Oral presentation session
Opportunities and challenges for countries in transition to overcome barriers to evidence-based policies and interventions
16:50
to
18:20
Networking zone 2 (N2)
Structured session
Prison and drugs: exploring social determinants and pathways to drug problem and incarceration
16:50
to
18:20
Central square 1 (C1)
Structured session
Reducing harm - obstacles and opportunities
16:50
to
18:20
Networking zone 1 (N1)
e-poster guided tour
Signals from the future: Exploring implications for drug policies
16:50
to
18:20
Central square 4 (C4)
Workshop
Treatment for cannabis use disorder: an update focusing in cultural characteristics
16:50
to
18:20
Knowledge market 4 (K4)
Structured session
Unpacking the neurobiology of cannabis use disorders and cannabinoids: findings from neuroimaging and experimental studies across different ages and world regions
16:50
to
18:20
Knowledge market 2 (K2)
Structured session
Young people, substance use and prevention
16:50
to
18:20
Knowledge market 3 (K3)
Oral presentation session
18:30
On the path towards elimination of hepatitis C – Models of care to reach people who inject drugs for testing and treatment
18:30
to
19:30
Knowledge market 4 (K4)
Structured session
Friday, 25 November
09:00
Insights from treatment II
09:00
to
10:30
Central square 2 (C2)
Oral presentation session
10:50
Gender differences and gender identities in drug use, addiction and interventions: why gender matters
10:50
to
12:20
Networking zone 3 (N3)
Structured session
Investigating adolescent substance use and risk behaviours in the Mediterranean region: where do we stand?
10:50
to
12:20
Networking zone 4 (N4)
Structured session
Portuguese Drug Policy Model. Achievements and challenges
10:50
to
12:20
Central square 2 (C2)
Structured session
Recreational drug use and risk
10:50
to
12:20
Central square 3 (C3)
Oral presentation session
Substance use and prison
10:50
to
12:20
Central square 1 (C1)
Oral presentation session
Substance use and sexual behaviours
10:50
to
12:20
Knowledge market 4 (K4)
Oral presentation session
13:20
Barriers in the implementation of harm reduction interventions in European prisons. From evidence to practice
13:20
to
14:50
Main stage
Structured session
Challenging issues for drug research
13:20
to
14:50
Central square 1 (C1)
Oral presentation session
Navigating the future of supervised consumption research and intervention: European and North American experiences
13:20
to
14:50
Central square 2 (C2)
Structured session
New advances in alcohol clinical research: evidence from three large National Institute for Health Research-funded randomised controlled trials
13:20
to
14:50
Networking zone 3 (N3)
Structured session
Substance use consequences and concerns
13:20
to
14:50
Networking zone 1 (N1)
e-poster guided tour
The experience of persons in homeless situation with alcohol related problems regarding a pharmacological harm reduction initiative
13:20
to
14:50
Knowledge market 4 (K4)
Structured session
Understanding drug use, risk and harm
13:20
to
14:50
Networking zone 2 (N2)
e-poster guided tour
Working with the most vulnerable
13:20
to
14:50
Central square 3 (C3)
Oral presentation session
Presentations
Wednesday, 23 November
10:50
Oral presentation
The implementation of ultra-portable devices for analysis of illicit drug in drug checking service of the Canton of Vaud (Switzerland, CH)
10:50
to
12:20
Central square 2 (C2)
Emilia Gianola
Oral presentation
Characteristics of acute ecstasy-related toxicity in multiple Dutch medical settings, from 2009 through 2018
10:50
to
12:20
Central square 2 (C2)
Lonja Schurmann
Oral presentation
Metabolite profiling of synthetic cathinones: towards the identification of consumption biomarkers in forensic and clinical settings
10:50
to
12:20
Central square 2 (C2)
Alexandra Antunes
Oral presentation
Substance Use and Substance Use Disorders in relation to COVID-19: Qualitative Experience of Users in Jordan
10:50
to
12:20
Central square 3 (C3)
Mayyada Wazaify
Oral presentation
Overdose deaths and the COVID-19 pandemic in British Columbia, Canada
10:50
to
12:20
Central square 3 (C3)
Alexis Crabtree
Oral presentation
1. Characteristics of suicides among overdose deaths in Norway in 2016-2020
10:50
to
12:20
Knowledge market 1 (K1)
Hilde Marie Erøy Edvardsen
Oral presentation
Changes in social work practice and support for people who use drugs during the Covid-19 pandemic – a case study of Malmö, Sweden
10:50
to
12:20
Central square 3 (C3)
Torkel Richert
Oral presentation
2. Individuals dying of overdoses related to pharmaceutical opioids differ from individuals dying of overdoses related to other substances
10:50
to
12:20
Knowledge market 1 (K1)
Svetlana Skurtveit
Oral presentation
3. Changes in primary cause of overdose deaths following liberalisations in opioid prescription practices and differences in overdose death correlates.
10:50
to
12:20
Knowledge market 1 (K1)
Linn Gjersing
Oral presentation
4. Fatal overdoses in a cohort of chronic pain patients
10:50
to
12:20
Knowledge market 1 (K1)
Aleksi Hamina
Oral presentation
Agreement between self-reported illicit drug use and biological samples: a systematic review and meta-analysis
10:50
to
12:20
Central square 2 (C2)
Chrianna Bharat
Oral presentation
Anti-doping knowledge and educational needs of Finnish pharmacists
10:50
to
12:20
Central square 2 (C2)
Jukka Koskelo
e-poster
Drug death related bereavement and recovery (The END-project)
10:50
to
12:20
Networking zone 1 (N1)
Birthe Møgster
e-poster
Effects of prolonged diacetylmorphine take-home prescription in Heroin assisted treatment in Switzerland
10:50
to
12:20
Networking zone 1 (N1)
Jonas Montagna
e-poster
Predicting the long-term effect of e-cigarette use on population health: A systematic review of modelling studies
10:50
to
12:20
Networking zone 1 (N1)
Giang Vu
e-poster
Barriers and Facilitators to Accessing Inpatient and Community Substance Use Treatment and Harm Reduction Services for People Who Use Drugs in Muslim Communities: A Systematic Narrative Review of Studies on Service Users and Providers Experiences
10:50
to
12:20
Networking zone 1 (N1)
Qutba Al Ghafri
Short communication
OurFutures: A suite of universal evidence-based eHealth programs to prevent substance use and mental ill-health among adolescents
10:50
to
12:20
Networking zone 4 (N4)
Lauren Gardner
Short communication
Telegram as a space for peer-leded harm reduction communities and netreach interventions
10:50
to
12:20
Networking zone 4 (N4)
Sara Rolando
Oral presentation
Drug use and attitudes toward COVID-19 vaccination in a representative sample of undergraduate students
10:50
to
12:20
Central square 3 (C3)
Stelios Stylianou
e-poster
Prevalence of HCV infection in vulnerable populations: DETECT-C program a real contribution to hepatitis C elimination in these groups in Spain
10:50
to
12:20
Networking zone 1 (N1)
Francisco Pascual
e-poster
ABC Training for Alcohol Use During an Abstinence Challenge (IkPas/NoThanks!): a pilot study
10:50
to
12:20
Networking zone 1 (N1)
Ting Pan
Oral presentation
3. Cannabis-related effects and harms: a scientific overview
10:50
to
12:20
Knowledge market 4 (K4)
Jakob Manthey
Oral presentation
4. Harm reduction for cannabis related problems in Europe and beyond
10:50
to
12:20
Knowledge market 4 (K4)
Iciar Indave
Short communication
Collaboration between prevention work and law enforcement in a nightlife drug-using setting: a vulnerable encounter?
10:50
to
12:20
Networking zone 4 (N4)
Annemie Coone
Short communication
Addressing Adherence and Success Rates of a Digital Self-Help Intervention for Alcohol and Substance Use with Machine Learning
10:50
to
12:20
Networking zone 4 (N4)
Anna Goudriaan
Short communication
What’s trending? Using social media to engage with hard to reach groups through an online survey
10:50
to
12:20
Networking zone 4 (N4)
Nicki Killeen
Short communication
Accessability of mental health services for people with substance use: findings from the SUMHIT project
10:50
to
12:20
Networking zone 4 (N4)
Jürgen Magerman
Oral presentation
2. Medical use of cannabis and cannabinoids: an overview of evidence
10:50
to
12:20
Knowledge market 4 (K4)
Mafalda Pardal
Short communication
Drug use and associated factors in Secondary Education in Basque Country
10:50
to
12:20
Networking zone 4 (N4)
Álvaro Moro Inchaurtieta
Oral presentation
5. Treatment of cannabis-related problems in Europe: a typology and evidence overview
10:50
to
12:20
Knowledge market 4 (K4)
Daniel Feingold
Short communication
What aspects of a drug checking service are important in a high-cost drug market?
10:50
to
12:20
Networking zone 4 (N4)
Raimondo Bruno
Introduction
1. Setting the scene: recent cannabis policy developments in European countries
10:50
to
12:20
Knowledge market 4 (K4)
Liesbeth Vandam
Oral presentation
Getting your addiction research published: seminar
10:50
to
12:20
Central square 4 (C4)
Richard Pates
13:20
Oral presentation
4. Boozebuster: A Mobile Intervention to Promote Low-Risk Drinking Habits in Young Adults –preliminary results
13:20
to
14:50
Insights zone 2 (I2)
Mieke Schulte
Discussion
Experiences with and opinions on (sub-)cultural adaptions and other forms of tailoring of digital addiction interventions to meet specific expectations of the target audience.
13:20
to
14:50
Insights zone 2 (I2)
Matthijs Blankers
Oral presentation
1. Developing a functional taxonomy for Digital Health Interventions in Addiction Services
13:20
to
14:50
Central square 2 (C2)
Joseph Tay Wee Teck
Oral presentation
1. Guided smartphone-based treatment for patients in opioid maintenance treatment in Iran -transdiagnostic treatment for substance use and common mental disorders
13:20
to
14:50
Insights zone 2 (I2)
Michael Schaub
Oral presentation
3. Immersive Virtual Reality in the Assessment and Treatment of Addictive Disorders: Current Status and Future Perspectives
13:20
to
14:50
Central square 2 (C2)
Simon Langener
Discussion
Are Digital Health Interventions for Addiction Services more likely to widen or narrow inequalities?
13:20
to
14:50
Central square 2 (C2)
Marica Ferri
Oral presentation
Discontinuing chronic benzodiazepine use for insomnia with blended care: results of a pragmatic cluster-RCT
13:20
to
14:50
Central square 3 (C3)
Kristien Coteur
Oral presentation
A cluster randomised controlled trial of an eHealth intervention to prevent multiple lifestyle risk behaviours among Australian adolescents: Results from the Health4Life Study
13:20
to
14:50
Central square 3 (C3)
Katrina Champion
Oral presentation
Digital technologies to prevent drug overdoses. A UK perspective
13:20
to
14:50
Central square 3 (C3)
Alberto Oteo
Oral presentation
Feasibility and efficacy of the S-Check App to change help seeking behaviour of people who use methamphetamine
13:20
to
14:50
Central square 3 (C3)
Krista Siefried
Oral presentation
2. Design and Testing of an Aftercare Mobile App for Substance Use Among Young Adults: An Interdisicplinary Approach in Denmark
13:20
to
14:50
Insights zone 2 (I2)
Adriana del Palacio-Gonzalez
Oral presentation
3. A guided digital intervention to reduce cannabis use: the ICan randomized controlled trial in the Netherland
13:20
to
14:50
Insights zone 2 (I2)
Marleen Olthof
e-poster
Crosstalk between autophagic intermediaries in the event of neurotoxic effects mediated by Synthetic Cannabinoids in NG108-15 cells
13:20
to
14:50
Networking zone 2 (N2)
Catarina Teixeira
Short communication
Anabolic-androgenic steroid dependence and muscle dysmorphia: an exploratory network analysis
13:20
to
14:50
Networking zone 4 (N4)
Morgan Scarth
e-poster
Treating cannabis use disorder in young adults with text-delivered peer network counseling: A large, multi-site, randomized clinical trial.
13:20
to
14:50
Networking zone 2 (N2)
Michael Mason
Short communication
The use of psychoactive substances among residents of long-term care facilities for the elderly : perspectives of residents, providers and administrators on the current situation, challenges and improvement of practices.
13:20
to
14:50
Networking zone 4 (N4)
Emile Bernier
e-poster
The arrival of Edibles in Quebec cannabis market : what can be done to minimize the health impact?
13:20
to
14:50
Networking zone 2 (N2)
Julie Loslier
Oral presentation
1. Drug laws indicators through the leximetric approach and relationship with effectiveness: the example of Italy in the period 1991-2018
13:20
to
14:50
Knowledge market 4 (K4)
Carla Rossi
e-poster
What difference will 2.5 grams make? Canada responds to British Columbia’s overdose crisis by agreeing to decriminalize possession of small amounts of drugs
13:20
to
14:50
Networking zone 2 (N2)
Lori Hanson
Oral presentation
2. Hospitalization risk profile of opioids users
13:20
to
14:50
Knowledge market 4 (K4)
Giada Minelli
Oral presentation
1. Overview of the updated ECDC/EMCDDA guidance on the prevention and control of infectious diseases among people who inject drugs
13:20
to
14:50
Networking zone 3 (N3)
Anne Bergenstrom,
Janelle Sandberg
Oral presentation
3. Using Supply Indicators in the Evaluation of Drug Supply Reduction – Challenges and Opportunities
13:20
to
14:50
Knowledge market 4 (K4)
Nicola Singleton
Oral presentation
2. Effectiveness of drug treatment, needle and syringe programmes and drug consumption rooms in the prevention of blood-borne viruses among people who inject drugs – updated evidence from reviews of empirical and mathematical modelling studies
13:20
to
14:50
Networking zone 3 (N3)
Matthew Hickman
Oral presentation
4. Estimating the size of the of illicit drug market – a critical review
13:20
to
14:50
Knowledge market 4 (K4)
Robin Udrisard
Oral presentation
3. Enhancing the HCV care cascade among people who inject drugs: a systematic review and considerations from an expert panel
13:20
to
14:50
Networking zone 3 (N3)
Ilonka Horváth
Oral presentation
5. Estimating the costs of the criminal justice system
13:20
to
14:50
Knowledge market 4 (K4)
Francesco Fabi
e-poster
Fifth of the inhabitants of Slovenia has already used cannabis or cannabis-derived products for health purposes or is considering it
13:20
to
14:50
Networking zone 2 (N2)
Ada Hocevar Grom
Discussion
Perspectives from government and civil society member(s) of the ECDC and EMCDDA expert panel on the key areas of intervention
13:20
to
14:50
Networking zone 3 (N3)
Janelle Sandberg,
Anne Bergenstrom,
Anna Tarján,
Mat Southwell,
Viktor Mravcik,
Annette Verster,
Slava Kushakov
Discussion
Integrating indicators and estimates
13:20
to
14:50
Knowledge market 4 (K4)
Peter H. Reuter
e-poster
The synthetic cannabinoid ADB-FUBINACA modulates epigenetic mechanisms during in vitro neuronal differentiation at biologically relevant concentrations
13:20
to
14:50
Networking zone 2 (N2)
Felix Carvalho
Short communication
Substance use and re-imprisonment: A longitudinal study of the Norwegian Offender Mental Health and Addiction (NorMA) cohort
13:20
to
14:50
Networking zone 4 (N4)
Nicoline Lokdam
e-poster
Profiles of individuals with cannabis-related disorders
13:20
to
14:50
Networking zone 2 (N2)
Marie-Josée Fleury
Short communication
The age of onset and quitting of drug use is rising
13:20
to
14:50
Networking zone 4 (N4)
Andreja Drev
e-poster
The effects of Synthetic Cannabinoids ADB-FUBINACA, AMB-FUBINACA, AB-CHMINACA and HU-308 on Differentiation and Proliferation of Brain NG108-15 Cells
13:20
to
14:50
Networking zone 2 (N2)
Carolina Freitas
Short communication
The impact of music on the addictive trajectory: perspective from young adults who experience homelessness.
13:20
to
14:50
Networking zone 4 (N4)
Elise Cournoyer Lemaire
Oral presentation
1. Overdose prevention and treatment implications of fentanyl use in the United States
13:20
to
14:50
Central square 4 (C4)
Alexander Walley
Oral presentation
2. Fentanyl related deaths and fentanyl acute toxicity presentations at emergency Departments in Europe, 2010-2020
13:20
to
14:50
Central square 4 (C4)
Peter Heudtlass
Oral presentation
3. High drug-related death mortality in Finland – special focus on young adults and teenagers
13:20
to
14:50
Central square 4 (C4)
Prikko Kriikku
Oral presentation
4. Intentional overdoses and associated mental health challenges, an overlooked sub-population of overdoses
13:20
to
14:50
Central square 4 (C4)
Thomas Clausen
Oral presentation
2. Digital Health Interventions: Petiscos from clinical practice
13:20
to
14:50
Central square 2 (C2)
Roya Vaziri
15:00
Oral presentation
2. Global markets, glocal threats: Early warning, preparedness, and response to new psychoactive substances in Europe
15:00
to
16:30
Central square 2 (C2)
Michael Evans-Brown
Oral presentation
3. Early Warning Systems are Critical to Drug Control Strategies to Protect Public Health and Safety
15:00
to
16:30
Central square 2 (C2)
Luli R. Akinfiresoye,
Terrence L. Boos
Oral presentation
4. NPS Discovery: An Open Access Early Warning System for the United States
15:00
to
16:30
Central square 2 (C2)
Barry K. Logan
Oral presentation
Utilising data linkage to describe and explore mortality among a retrospective cohort of individuals admitted to residential substance use treatment.
15:00
to
16:30
Central square 3 (C3)
Tisdale Calvert
Oral presentation
It is logically not possible to quantify the number of indirect deaths
15:00
to
16:30
Central square 3 (C3)
Alfred Uhl
Oral presentation
Mortality and Morbidity in Patients in Opioid Maintenance Treatment
15:00
to
16:30
Central square 3 (C3)
Roman Gabrhelík
Oral presentation
Trends in mortality from alcohol, opioid, and combined alcohol and opioid poisonings by sex, educational attainment and race and ethnicity for the United States 2000-2018.
15:00
to
16:30
Central square 3 (C3)
Charlotte Buckley
Oral presentation
Mortality consequences of misuse of psychoactive prescription drugs in Portugal - the MisuMedPT project
15:00
to
16:30
Central square 3 (C3)
Ana Araújo
Oral presentation
5. International cooperation to address global public health harms caused by novel psychoactive substances while protecting access to medicines
15:00
to
16:30
Central square 2 (C2)
Dilkushi Poovendran
Oral presentation
1. Early warning on emerging drug threats at the international level – opportunities and challenges
15:00
to
16:30
Central square 2 (C2)
Martin Raithelhuber
Oral presentation
2. The rapid expansion of DCRs/SIFs in Canada in the context of a public health emergency
15:00
to
16:30
Insights zone 3 (I3)
Jane Buxton
Oral presentation
3. Denmark: A successful case study in community advocacy culminating in several sanctioned SIFs
15:00
to
16:30
Insights zone 3 (I3)
Michael Lodberg Olsen
Oral presentation
4. How to run an unsanctioned overdose prevention van; experiences from Glasgow 2020-2021
15:00
to
16:30
Insights zone 3 (I3)
Peter H. Krykant
Discussion
Discussion: synergies and challenges each region faces in relation to the model/s within which DCRs operate
15:00
to
16:30
Insights zone 3 (I3)
Jane Mounteney
Oral presentation
1. Twenty-one years of operation at the Uniting Sydney Medically Supervised Injecting Centre (MSIC) Australia
15:00
to
16:30
Insights zone 3 (I3)
Marianne Jauncey
Oral presentation
Anabolic androgenic steroid use population size estimation: a first stage study utilising a Delphi exercise
15:00
to
16:30
Knowledge market 4 (K4)
Vivian Hope
Oral presentation
Prevalence and socio-demographics correlates of cannabis vaping: Results from the 2018 & 2019 International Cannabis Policy Study
15:00
to
16:30
Knowledge market 4 (K4)
Gary Chan
Oral presentation
Systematic review and meta-analysis of the prevalence of prescription opioid dependence in patients with chronic non cancer pain (CNCP) treated with opioid painkillers
15:00
to
16:30
Knowledge market 4 (K4)
Kyla Thomas
Oral presentation
Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: the ETHOS Engage Study
15:00
to
16:30
Knowledge market 4 (K4)
Jason Grebely
Oral presentation
How does risk prevention (not) work? Learning from the realist, pragmatic, cluster-randomised trial of the RISKIT-CJS programme (with a null result)
15:00
to
16:30
Knowledge market 4 (K4)
Nadine Hendrie
Oral presentation
3 Scenarios, 3 Alternative Addiction Futures for 2040
15:00
to
16:30
Central square 4 (C4)
Jessica Prendergast
16:50
Oral presentation
1. The standard THC unit
16:50
to
18:20
Main stage
Tom Freeman
Oral presentation
2. Paving the Way for Improved Data Collection on Cannabis Use
16:50
to
18:20
Main stage
Susan Weiss
Oral presentation
3. The International Cannabis Toolkit (iCannToolkit): a first necessary step to integrate global multidisciplinary evidence on cannabis related risks and benefits
16:50
to
18:20
Main stage
Valentina Lorenzetti
Oral presentation
4. From standard drinks to the cannabis toolkit
16:50
to
18:20
Main stage
Antoni Gual
Oral presentation
5. Medical use and novel cannabinoids
16:50
to
18:20
Insights zone 3 (I3)
Robyn Robertson
Oral presentation
An international rapid review of the needs and an indirect estimate of the national prevalence of women who use substances and endure domestic violence.
16:50
to
18:20
Central square 3 (C3)
Catherine Comiskey
Oral presentation
What are the attitudes of pregnant women and mothers concerning maternal alcohol use, and what factors are associated with increased maternal drinking?
16:50
to
18:20
Central square 3 (C3)
Abi Rose
Oral presentation
Identifying the needs of mothers in substance use treatment services using electronic health records
16:50
to
18:20
Central square 3 (C3)
Martha Canfield
Oral presentation
Metzineres. Environments of Shelter for Womxn who use drugs surviving violence
16:50
to
18:20
Central square 3 (C3)
Aura Roig Forteza
Oral presentation
1. Experimental studies on cannabis and driving impairment
16:50
to
18:20
Insights zone 3 (I3)
Tom Arkell
Oral presentation
Prevalence of Tobacco Smoking in Austria. Differences between Women and Men
16:50
to
18:20
Central square 3 (C3)
Irene Schmutterer
Oral presentation
2. Epidemiological studies on cannabis and crash risk
16:50
to
18:20
Insights zone 3 (I3)
Eef Theunissen
Oral presentation
3. Toxicology: detection of THC impairment
16:50
to
18:20
Insights zone 3 (I3)
Jan Ramaekers
Oral presentation
4. Policy and legislation
16:50
to
18:20
Insights zone 3 (I3)
Brendan Hughes
Short communication
Successful microelimination of HCV among patients in the Romanian prison system
16:50
to
18:20
Networking zone 3 (N3)
Adrian Abagiu
Short communication
The synthetic cannabinoids ADB-FUBINACA and THJ-2201 decrease mitochondrial activity and ATP levels during neurodifferentiation of NG108-15 cells
16:50
to
18:20
Networking zone 3 (N3)
Rui Filipe Malheiro
Short communication
In vitro toxicity of the synthetic cannabinoids THJ-2201 and ADB-FUBINACA to human astrocytes
16:50
to
18:20
Networking zone 3 (N3)
Rafaela Silva
Short communication
Virtual Opioid User: Simulating the Effects of Counterfeit Pill Prevalence with a Control Theory Model
16:50
to
18:20
Networking zone 3 (N3)
Alexander Preiss
Short communication
The Influence of the Synthetic Cannabinoids AMB-FUBINACA, ADB-FUBINACA, AB-CHMINACA and THJ-2201 on In Vitro Viability and Senescence of SH-SY5Y Cells and Primary Rat Hippocampal Neurons
16:50
to
18:20
Networking zone 3 (N3)
Rita Roque Bravo
Oral presentation
1. The role of social work in agency processes - empirical study using the example of people who use illicit substances with a history of imprisonment
16:50
to
18:20
Networking zone 1 (N1)
Daniela Jamin
Oral presentation
2. Social work with drug users in a probation system of Kyrgyzstan
16:50
to
18:20
Networking zone 1 (N1)
Estebes uulu Tynchtyk
Oral presentation
3. Health and social welfare in prisons in the Republic of Kazakhstan – women with HIV and the role of the social worker
16:50
to
18:20
Networking zone 1 (N1)
Dalida Mukasheva
Oral presentation
Findings from treatment facility survey (EFSQ) in Lebanon’
16:50
to
18:20
Networking zone 2 (N2)
Zeinab Abbas
Oral presentation
European facility survey questioner (EFSQ) for Palestinian substance use disorder (SUD) treatment facilities.
16:50
to
18:20
Networking zone 2 (N2)
Saed Bilbeisi
Oral presentation
European treatment facility survey in Georgia
16:50
to
18:20
Networking zone 2 (N2)
Irakli Natsvlishvili
Oral presentation
Drug treatment facilities survey, Tunisia 2020
16:50
to
18:20
Networking zone 2 (N2)
Hajer Aounallah-Skhiri
Short communication
Impact of the COVID-19 pandemic on drug use in the Republic of North Macedonia
16:50
to
18:20
Networking zone 3 (N3)
Sanja Prosheva
Short communication
Non-pharmacological treatment interventions in UK drug and alcohol services: an exploratory study
16:50
to
18:20
Networking zone 3 (N3)
Karen Megranahan
Thursday, 24 November
09:00
Oral presentation
2. New challenges in drug monitoring: wastewater analysis as an alternative indicators for rapid epidemiological assessment of drug use trend
09:00
to
10:30
Knowledge market 4 (K4)
José Benito Quintana
Oral presentation
3. Promotion of health regarding the problematic drug use through interventions in educational and primary addiction treatment settings
09:00
to
10:30
Knowledge market 4 (K4)
Victor Villanueva
Oral presentation
4. Translational research as a necessary actor for fighting addiction: RIAPAd as a coordinated national cooperative framework
09:00
to
10:30
Knowledge market 4 (K4)
Fernando Rodriguez De Fonseca
Discussion
What is next on Addiction Research? A responsible innovative approach to societal changes in Addiction
09:00
to
10:30
Knowledge market 4 (K4)
Marta Torrens,
Fernando Rodriguez De Fonseca
Oral presentation
1. Implementing patient-reported experiences (PROMs and PREMs) to improve the engagement of patients in treatment services
09:00
to
10:30
Knowledge market 4 (K4)
Joan-Ignasi Mestre-Pintó
Oral presentation
Stakeholders’ perceptions about their position and the dynamics between the stakeholders within Swedish drug policy field
09:00
to
10:30
Central square 2 (C2)
Tuulia Lerkkanen
Oral presentation
Switching from a criminalisation to a public health approach to injecting drug use in Eastern Europe and Central Asia: a modelling analysis of the costs and impact on HIV transmission
09:00
to
10:30
Central square 2 (C2)
Zoe Ward
Oral presentation
Addressing intimate partner abuse (IPA) perpetrated by heterosexual men in substance use treatment: the ADVANCE programme
09:00
to
10:30
Central square 2 (C2)
Gail Gilchrist
Oral presentation
ROSE: A peer-led intervention to support peer workers in overdose response settings in British Columbia
09:00
to
10:30
Central square 2 (C2)
Fred Cameron
10:50
Oral presentation
4. How do you become involved in hybrid digital drug markets: Identifying explanations in a qualitative interview study with social media sellers
10:50
to
12:20
Central square 2 (C2)
Jakob Demant
Oral presentation
Mental health and associations with tobacco smoking and quitting behaviour in the population of Germany
10:50
to
12:20
Central square 3 (C3)
Sabrina Kastaun
Oral presentation
Neuropsychology of Addictions in Therapeutic Communities: assessing and understanding cognitive recovery through a residential treatment of substance use disorders
10:50
to
12:20
Central square 3 (C3)
Simon Deniel
Oral presentation
Administration matters! A retrospective cohort study of medication dispensing at pharmacies
10:50
to
12:20
Knowledge market 3 (K3)
Birgitte Thylstrup
Oral presentation
Binge alcohol intake triggers microglial activation and TNF-dependent aberrant synaptic pruning, causing synapse loss and increased anxiety
10:50
to
12:20
Central square 3 (C3)
Teresa Summavielle
Oral presentation
Primary Care Provider expectations of addiction services and patients in Spain.
10:50
to
12:20
Knowledge market 3 (K3)
Pablo Barrio
Oral presentation
High dose anabolic steroid use and facial emotion recognition, the hormonal influence on social cognition.
10:50
to
12:20
Central square 3 (C3)
Astrid Bjørnebekk
Oral presentation
Optimising take home naloxone intervention delivery in the community (retail) pharmacy setting.
10:50
to
12:20
Knowledge market 3 (K3)
Jennifer Scott
Oral presentation
Practitioner perspectives on working with older patients in opioid agonist treatment (OAT) in Norway
10:50
to
12:20
Knowledge market 3 (K3)
John Todd-kvam
Oral presentation
Integrating harm reduction in homelessness services. The HR4H Key Principles
10:50
to
12:20
Knowledge market 3 (K3)
Roberto Perez Gayo
Oral presentation
1. Synthetic opioids in Sweden: Analyses of public webforum discussions
10:50
to
12:20
Central square 2 (C2)
Kim Moeller
Oral presentation
2. From the jungle to the street: Country-level variation and demographic correlates of cocaine prices
10:50
to
12:20
Central square 2 (C2)
Rasmus Munksgaard
Oral presentation
3. Illegal drug markets on social media: Locally bound actors on global platforms
10:50
to
12:20
Central square 2 (C2)
Silje Anderdal Bakken
Short communication
Mutual help groups for women who use drugs, as a community-led gender sensitive harm reduction response
10:50
to
12:20
Networking zone 4 (N4)
Lígia Parodi
Oral presentation
1. The 4 pillar drug policy and city overview
10:50
to
12:20
Central square 4 (C4)
Andrea Weiss
Oral presentation
1. Steps forward in an attempt of OKANA to widen harm reduction to risk reduction: entries and facilities within a new concept based on the real needs
10:50
to
12:20
Knowledge market 4 (K4)
Athanasios Theocharis
Oral presentation
3. t-alk' and 'City' – low-threshold meeting places for a diverse clientele
10:50
to
12:20
Central square 4 (C4)
Larissa Stämpfli
Oral presentation
2. Streetwork and Outreach Networking
10:50
to
12:20
Knowledge market 4 (K4)
Lagakou Litsa
Oral presentation
2. Surpervised drug consumption facilities (SDCF)
10:50
to
12:20
Central square 4 (C4)
Janine Lanz
Oral presentation
3. Direct access to OST treatment and integrated therapy: Lessons learned from streets to community
10:50
to
12:20
Knowledge market 4 (K4)
Nikos Avgerinos
Oral presentation
4. sip züri' - entry control of safe injection facilities, and from social space management to social ambulance
10:50
to
12:20
Central square 4 (C4)
Mara Brügger
Oral presentation
4. Harm Reduction and Covid 19: Hostel 'IONIS', an example of a holistic intervention for homeless drug users
10:50
to
12:20
Knowledge market 4 (K4)
Foteini Leobilla
Oral presentation
5. Flora Dora' and prostitution area team: outreach social work for sexworkers and low-threshold counselling on the spot
10:50
to
12:20
Central square 4 (C4)
Ursula Kocher
Discussion
Challenges faced, political will, societal willingness and community approach of the harm reduction policy.
10:50
to
12:20
Knowledge market 4 (K4)
Athanasios Theocharis
Short communication
Gender differences in cannabis use disorder symptoms: A network analysis
10:50
to
12:20
Networking zone 4 (N4)
Emese Kroon
Short communication
Photovoicing interconnected sources of recovery capital of women with a drug use history
10:50
to
12:20
Networking zone 4 (N4)
Jessica De Maeyer
Short communication
Complex social and health care needs of women who seek addiction treatment: listening to their voices to guide long-term integrated services that take into account gender
10:50
to
12:20
Networking zone 4 (N4)
Karine Bertrand
Short communication
Exploring intersections between gender and drug use in East and Southern Africa
10:50
to
12:20
Networking zone 4 (N4)
Charity Monareng
Short communication
Mutual support groups among women who use drugs in a community context as a comprehensive and affordable strategy to reduce inequalities
10:50
to
12:20
Networking zone 4 (N4)
Joana Canedo
13:20
Oral presentation
Effectiveness of e-cigarettes for smoking cessation in the German population - a comparison with nicotine replacement therapy and no use of evidence-based support (DEBRA study)
13:20
to
14:50
Central square 3 (C3)
Daniel Kotz
Oral presentation
The lifetime costs and benefits of subsidizing the cost of nicotine replacement therapy in Sweden
13:20
to
14:50
Central square 3 (C3)
Inna Feldman
Oral presentation
Cessation of Smoking Trial in the Emergency Department- interim results
13:20
to
14:50
Central square 3 (C3)
Ian Pope
Oral presentation
Motivation to stop smoking in the German population: recent trends and associated factors (DEBRA study)
13:20
to
14:50
Central square 3 (C3)
Benjamin Borchardt
Oral presentation
2. Estimating the prevalence of opioid dependence in New South Wales from multiple data sources: case study application of a Bayesian modelling approach
13:20
to
14:50
Central square 2 (C2)
Hayley E. Jones
Oral presentation
3. Estimates of people who injected drugs within the past 12 months in France
13:20
to
14:50
Central square 2 (C2)
Eric Janssen
Oral presentation
4. How many people injected illicit drugs in the European Union in 2019?
13:20
to
14:50
Central square 2 (C2)
Filippo Pericoli
Oral presentation
1. Estimates of people who injected drugs within the last 12 months in Belgium
13:20
to
14:50
Central square 2 (C2)
Luk Van Baelen
Oral presentation
5. Updated global estimates of prevalence of People Who Inject Drugs and coverage of harm reduction – what has changed between 2017 and 2021
13:20
to
14:50
Central square 2 (C2)
Samantha Colledge-Frisby
Oral presentation
What will the future nicotine market look like in a post-smoking era?
13:20
to
14:50
Central square 3 (C3)
Karl Erik Lund
Short communication
Harm Reduction for Chemsex in Lisbon: community-based interventions for a hard-to-reach group, during the COVID-19 pandemic
13:20
to
14:50
Networking zone 3 (N3)
Filipe Couto Gomes
Short communication
Z-Drugs Dependence: An Awakening Truth
13:20
to
14:50
Networking zone 3 (N3)
Afonso Homem De Matos
Oral presentation
1. Association of cannabis and tobacco use with incident anxiety, mood and psychotic disorders: a systematic review
13:20
to
14:50
Knowledge market 1 (K1)
Chloe Burke
Oral presentation
3. The Cannabis And Tobacco Cessation Advice (CATCA) project: A mixed method study exploring UK stop smoking practitioners’ knowledge, attitudes and practices around co-use
13:20
to
14:50
Knowledge market 1 (K1)
Maria Duaso
Oral presentation
4. Changes in tobacco use among people with cannabis use disorder treated in programs
13:20
to
14:50
Knowledge market 1 (K1)
Cristina Martínez
Oral presentation
2. Quitting experiences, attitudes and beliefs amongst UK young adult co-smokers: A qualitative interview study
13:20
to
14:50
Knowledge market 1 (K1)
Hannah Walsh
Short communication
Evaluating Cracks in the Ice – a digital health initiative to support families, health workers and communities affected by crystal methamphetamine (‘ice’)
13:20
to
14:50
Networking zone 3 (N3)
Steph Kershaw
Short communication
Exclusive therapeutic use of cannabis in France: characteristics and use patterns in a large sample of daily users
13:20
to
14:50
Networking zone 3 (N3)
Martin Bastien
Short communication
Psychoactive substance use among Serbian adults – results from online survey
13:20
to
14:50
Networking zone 3 (N3)
Biljana Kilibarda
Oral presentation
3. Drug checking in DCRs in Switzerland: a new harm reduction tool?
13:20
to
14:50
Central square 4 (C4)
Florian Meyer,
Pierre Esseiva
Oral presentation
4. A qualitative exploration of three hypothetical models of drug checking service delivery in a Scottish context
13:20
to
14:50
Central square 4 (C4)
Danilo Falzon
Oral presentation
1. Implementing community-based drug checking services in two Canadian provinces: lessons learned and ways forward
13:20
to
14:50
Central square 4 (C4)
Karen McDonald
Oral presentation
2. Tailoring drug checking services to Drug Consumption Rooms
13:20
to
14:50
Central square 4 (C4)
Mireia Ventura
Short communication
The epigenetic effects of cannabis exposure and their link to behavior and emotional manifestations – a scoping review
13:20
to
14:50
Networking zone 3 (N3)
Ana Sofia Machado
15:00
Oral presentation
1. Combining Psychedelic Treatments with Current Substance Use Disorder Treatments
15:00
to
16:30
Main stage
Johannes Thrul
Oral presentation
2. Improving the self: Psychedelic drug use and the enhancement-treatment debate
15:00
to
16:30
Main stage
Margit Anne Petersen
Oral presentation
3. Psychedelics in psychiatry: focus on evidence and mechanisms of relevance to affective disorders and addictions
15:00
to
16:30
Main stage
David Erritzoe
Oral presentation
Examining health care from the drug user perspective: what works, what doesn't and what needs to change
15:00
to
16:30
Central square 3 (C3)
Mary Ellen Harrod
Oral presentation
An Evaluation of the Co-Design of an Anti-Stigma Training Programme
15:00
to
16:30
Central square 3 (C3)
Sonam Prakashini Banka
Oral presentation
Once you’ve addressed your drinking, we’ll address your mental health': A qualitative exploration of patient and providers’ experiences of services for co-occurring heavy drinking and depression in North East England
15:00
to
16:30
Central square 3 (C3)
Amy O'Donnell
Oral presentation
Police officers’ attitudes and practices toward harm reduction services in Sweden – a qualitative study
15:00
to
16:30
Central square 3 (C3)
Johan Nordgren
Oral presentation
1. New Psychoactive Substance Presentations to the Euro-DEN Plus Network
15:00
to
16:30
Central square 2 (C2)
Benjamin Crulli
Oral presentation
2. The clinical impact of ethanol co-use in patients with acute drug toxicity involving the use of central nervous system depressant recreational drugs
15:00
to
16:30
Central square 2 (C2)
Eva-Carina Heier
Oral presentation
3. Variation in the drugs involved in acute drug toxicity presentations based on age and sex within the Euro-DEN Plus dataset
15:00
to
16:30
Central square 2 (C2)
Òscar Miró
Oral presentation
4. Deaths among acute drug toxicity presentations to the Euro-DEN Plus Network, 2014-2020
15:00
to
16:30
Central square 2 (C2)
Isabelle Giraudon
Oral presentation
Who is using take-home naloxone? An examination of super-savers
15:00
to
16:30
Central square 3 (C3)
Desiree Eide
e-poster
Risk of Relapse Among Opioid-Dependent Patients Treated With Extended-Release Naltrexone or Buprenorphine-Naloxone: A Randomized Clinical Trial
15:00
to
16:30
Networking zone 1 (N1)
Arild Opheim
e-poster
Real-world effectiveness of various pharmacological treatments in methamphetamine/amphetamine use disorders
15:00
to
16:30
Networking zone 1 (N1)
Milja Heikkinen
e-poster
Life satisfaction among individuals with opioid use disorder receiving extended-release naltrexone: A 12-week randomized controlled trial and a 36-week follow-up
15:00
to
16:30
Networking zone 1 (N1)
Zhanna Gaulen
e-poster
Starting Buprenorphine therapy. Challenges and difficulties
15:00
to
16:30
Networking zone 1 (N1)
Esmeralda Thoma
e-poster
Psychostimulant-induced neuroinflammation: the protective role of IL-10
15:00
to
16:30
Networking zone 1 (N1)
Ana Isabel Silva
e-poster
Characterising the neurobiology of detoxification in opiate dependence: is there a role for NK1 antagonism to improve outcomes?
15:00
to
16:30
Networking zone 1 (N1)
Katherine Herlinger
Oral presentation
3. Development of tailored prevention intervention packages
15:00
to
16:30
Knowledge market 4 (K4)
Magdalena Rowicka
e-poster
Outcome measurement and evaluation as a routine practice in alcohol and other drug services in Belgium (OMER-BE)
15:00
to
16:30
Networking zone 1 (N1)
Amine Zerrouk
Oral presentation
1. Aims, scope and methodology of IMPRESA
15:00
to
16:30
Knowledge market 4 (K4)
Dovilė Mačiulytė
e-poster
Medically supervised opioid withdrawal treatment: is it possible to predict the successful outcome?
15:00
to
16:30
Networking zone 1 (N1)
Artūras Barkus
Oral presentation
2. Results of the literature review and the Delphi expert consensus finding process on Methamphetamine Prevention Interventions
15:00
to
16:30
Knowledge market 4 (K4)
Benjamin Petruželka
e-poster
Patient-reported outcomes of subcutaneous depot buprenorphine treatment in Australian correctional centres
15:00
to
16:30
Networking zone 1 (N1)
Nadine Ezard
Oral presentation
4. The RE-AIM framework for evaluating implementation processes and public health impact
15:00
to
16:30
Knowledge market 4 (K4)
Harald Lahusen
Oral presentation
0. Insights into acute recreational drug and NPS toxicity: an update from the Euro DEN Plus Project: Introduction
15:00
to
16:30
Central square 2 (C2)
Paul Dargan
16:50
Oral presentation
The acceptability and feasibility of implementing and evaluating the Parents under Pressure (PuP) parenting programme with opioid-dependent fathers and their families: results from the PuP4Dads study.
16:50
to
18:20
Central square 3 (C3)
Anne Whittaker
Oral presentation
1. Cannabis use disorder and the brain: What’s culture got to do with it?
16:50
to
18:20
Knowledge market 2 (K2)
Janna Cousijn
Oral presentation
2. Resting state functional connectivity of the dorsal attention network in cannabis use disorder: a fMRI study
16:50
to
18:20
Knowledge market 2 (K2)
Lisa-Marie Greenwood
Oral presentation
3. Brain reward function in young people with a dsm-5 diagnosis of Cannabis Use Disorder: a fMRI study
16:50
to
18:20
Knowledge market 2 (K2)
Valentina Lorenzetti
Oral presentation
Laughing gas (N2O) in The Netherlands: where a quick rise in use required action
16:50
to
18:20
Knowledge market 3 (K3)
Desiree Spronk
Oral presentation
Identifying subgroups of Dutch cannabis users based on help-seeking preferences: a latent class analysis
16:50
to
18:20
Knowledge market 3 (K3)
Marleen Olthof
Oral presentation
A National Recovery Study in Higher Education Institutions in Ireland
16:50
to
18:20
Knowledge market 3 (K3)
Ivers Jo-Hanna
Oral presentation
4. Neural response to reward anticipation after acute exposure to cannabis with and without cannabidiol in adults and adolescents
16:50
to
18:20
Knowledge market 2 (K2)
Martine Skumlien
Oral presentation
Identification of cannabis user profiles and their engagement with polydrug use among respondents of the European Web Survey on Drugs: findings from Luxembourg
16:50
to
18:20
Knowledge market 3 (K3)
Tom Kugener
Oral presentation
5. Acute effects of four CBD:THC ratios on attentional bias to cannabis and food cues: a randomized, double-blind, crossover study
16:50
to
18:20
Knowledge market 2 (K2)
Dominic Oliver
Oral presentation
E-cigarette use and conventional cigarette smoking among high school students in 35 European countries: findings from the 2019 ESPAD survey
16:50
to
18:20
Knowledge market 3 (K3)
Sonia Cerrai
Short communication
The Treatment of Addictions in Portugal - What Future?
16:50
to
18:20
Networking zone 3 (N3)
João Feliz
e-poster
Hepatitis C seroprevalence and associated factors among people who inject drugs (PWID) in Estonia
16:50
to
18:20
Networking zone 1 (N1)
Sigrid Vorobjov
Oral presentation
6. European Prevention Curriculum – a tool for disseminating effective modern prevention approaches and facilitating well-informed choices about funding and implementation priorities: reflections from Georgia
16:50
to
18:20
Networking zone 2 (N2)
Jana D. Javakhishvili
Oral presentation
1. Pharmacological treatments for cannabis use disorder
16:50
to
18:20
Knowledge market 4 (K4)
Albert Batalla
e-poster
Take-Home Naloxone and risk management among people who survived an opioid overdose; a qualitative analysis informed by drug, set and setting
16:50
to
18:20
Networking zone 1 (N1)
Elin Holmén
Oral presentation
3. Capacity building for practitioners on evidence-based drug treatment interventions aligned with EU quality standards and tailored to national needs
16:50
to
18:20
Networking zone 2 (N2)
Anna Tarján
Oral presentation
2. Motivational Interviewing for CUD: current situation and gaps
16:50
to
18:20
Knowledge market 4 (K4)
Hugo López Pelayo
e-poster
Mortality and causes of death among persons with alcohol use disorder only versus persons with opioid dependence: results from a 19-year prospective cohort study.
16:50
to
18:20
Networking zone 1 (N1)
Ivar Skeie
Oral presentation
4. Capacity building for practitioners on evidence-based drug treatment interventions aligned with EU quality standards and tailored to national needs: reflections from Georgia
16:50
to
18:20
Networking zone 2 (N2)
David Otiashvili
Oral presentation
3. Cultural and language adaptation to Spanish of CANnabis DISorder Program (CANDIS)
16:50
to
18:20
Knowledge market 4 (K4)
Pablo Guzmán
e-poster
Identifying and tracking cases of suspected unintentional drug overdose deaths in near real-time using the Suspected Potential Overdose Tracker (SPOT)
16:50
to
18:20
Networking zone 1 (N1)
Karli Hochstatter
Oral presentation
5. The importance of an evidence-based approach in the development of a national drug policy
16:50
to
18:20
Networking zone 2 (N2)
Artur Malczewski
Oral presentation
4. Pros and Cons of Group Therapy for Cannabis Use Disorders: Is it an opportunity for cultural adaptation?
16:50
to
18:20
Knowledge market 4 (K4)
Mercè Balcells
e-poster
Wearable technologies that may prevent, detect or respond to opioid overdose: a scoping review.
16:50
to
18:20
Networking zone 1 (N1)
Basak Tas
Discussion
European Prevention Curriculum
16:50
to
18:20
Networking zone 2 (N2)
Gregor Burkhart
Oral presentation
Ayahuasca-assisted addiction treatment in Peru: qualitative results from a multi-year, mixed-methods study
16:50
to
18:20
Central square 3 (C3)
Olivia Marcus
Short communication
Outreach for socially marginalized trimorbid veterans in Denmark – preliminary results
16:50
to
18:20
Networking zone 3 (N3)
Henrik Thiesen
Oral presentation
EXtended-release Pharmacotherapy for Opioid Use Disorder (EXPO)
16:50
to
18:20
Central square 3 (C3)
John Marsden
Short communication
A Feasibility Study of Mentalization Based Therapy for Antisocial personality disorder with substance use disorder in Norway- preliminary findings
16:50
to
18:20
Networking zone 3 (N3)
Katharina Morken
Oral presentation
Characteristics of concerned persons (CPs) accessing treatment services in their own right: A secondary analysis of Irish health data for 2010-2020.
16:50
to
18:20
Central square 3 (C3)
Cathy Kelleher
Short communication
Working in drug treatment and health care facilities
16:50
to
18:20
Networking zone 3 (N3)
Maitena Milhet
Short communication
Incidence and determinants of CoVID-19 in patients seeking treatment of Substance Use Disorder: a population-based linkage study
16:50
to
18:20
Networking zone 3 (N3)
Irene Lana
e-poster
Harm reduction behaviors are associated with carrying naloxone among patients on methadone treatment.
16:50
to
18:20
Networking zone 1 (N1)
Zofia Kozak
Oral presentation
1. Assisting drug policies in the quest for an evidence-base: challenges related to the development of a National Action Plan for the Drug Information System
16:50
to
18:20
Networking zone 2 (N2)
Viktor Mravcik
Short communication
Perspectives Pathways and Priorities of People with Lived and Living Experience of Substance Use: Informing Policies (P5 Project YXE)
16:50
to
18:20
Networking zone 3 (N3)
Barbara Fornssler
e-poster
High smoking and low cessation rates among patients in treatment for opioid and other substance use disorders
16:50
to
18:20
Networking zone 1 (N1)
Endre D. Bjørnestad
Oral presentation
2. Shared responsibilities among different stakeholders in the quest for evidence: experiences from Georgia
16:50
to
18:20
Networking zone 2 (N2)
Ketevan Sarajishvili
Oral presentation
2. Characteristics associated with drug use during the current detention – results from prison surveys in 4 EU countriessurveys in 4 EU countries
16:50
to
18:20
Central square 1 (C1)
Els Plettinckx
Oral presentation
5. Social determinants, health service contacts and incarceration among all those dying from an accidental overdose 2010-2018 in Norway
16:50
to
18:20
Central square 1 (C1)
Ellen J. Amundsen
Oral presentation
3. Reimprisonment rates among men who inject drugs in Victoria, Australia
16:50
to
18:20
Central square 1 (C1)
Ashleigh C. Stewart
Oral presentation
4. Adverse childhood experiences, substance use, and involvement with correctional services
16:50
to
18:20
Central square 1 (C1)
Richard Pates
Oral presentation
6. Wasted': the complex trajectories from incarceration to recovery. A personal experience
16:50
to
18:20
Central square 1 (C1)
Mark Johnson Ferguson
Discussion
Common pathways to problematic drug use and incarceration and lessons learnt for policy and practice
16:50
to
18:20
Central square 1 (C1)
Liesbeth Vandam
Oral presentation
1. Use pathways in prison. A French literature review
16:50
to
18:20
Central square 1 (C1)
Caroline Protais
Oral presentation
Signals from the future: Exploring implications for drug policies
16:50
to
18:20
Central square 4 (C4)
Laura Smit-rigter
18:30
Oral presentation
3. HCV treatment uptake among marginalized people who inject drugs in Norway: A registry-based study, and the Progress towards elimination of hepatitis C among people who inject drugs in Norway
18:30
to
19:30
Knowledge market 4 (K4)
Knut Boe Kielland
Oral presentation
2. Opportunistic Treatment of Hepatitis C Virus Infection: A pragmatic stepped-wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs (OPPORTUNI-C)
18:30
to
19:30
Knowledge market 4 (K4)
Olav Dalgard
Oral presentation
1. Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program. And new models to reach those hard to reach; results from Point of Care testing and treatment in a nurse led and a peer led mobile clinic
18:30
to
19:30
Knowledge market 4 (K4)
Linda Wüsthoff
Friday, 25 November
09:00
Oral presentation
Determinants of recovery capital among persons in early and stable recovery from drug addiction
09:00
to
10:30
Central square 2 (C2)
Wouter Vanderplasschen
Oral presentation
An exploratory analysis of actigraphy and sleep diaries in a methamphetamine withdrawal clinical trial
09:00
to
10:30
Central square 2 (C2)
Liam Acheson
Oral presentation
Recovery and substitute addictions
09:00
to
10:30
Central square 2 (C2)
Deborah Louise Sinclair
10:50
Oral presentation
2. Gender differences in drug use from a social perspective
10:50
to
12:20
Networking zone 3 (N3)
Nuria Romo
Oral presentation
3. Sex differences in drug use and drug addiction from a neuroscience perspective
10:50
to
12:20
Networking zone 3 (N3)
Anne Marije Kaag
Oral presentation
4. Using an intersectional risk environment approach to understand health and drug outcomes: Looking across social locations
10:50
to
12:20
Networking zone 3 (N3)
Alexandra B. Collins
Oral presentation
6. Implementing a gender dimension in drug policy and practice: findings from the Pompidou Group handbook for practitioners and decision makers
10:50
to
12:20
Networking zone 3 (N3)
Sarah Morton
Oral presentation
Size Matters: Comparing the MDMA content and weight of ecstasy tablets submitted to European drug checking services in 2012-2021
10:50
to
12:20
Central square 3 (C3)
Ruben Vrolijk
Oral presentation
Shifting stages of ATS use and evidence-based intervention for risk reduction
10:50
to
12:20
Central square 3 (C3)
Nienke Liebregts
Oral presentation
Polydrug use typologies of regular ecstasy users visiting electronic dance music events in the United Kingdom and the Netherlands: A Latent Class Analysis.
10:50
to
12:20
Central square 3 (C3)
Ruben Van Beek
Oral presentation
Drug use and harm reduction in techno parties: some lessons learned from 20 years of fieldwork
10:50
to
12:20
Central square 3 (C3)
Fabrice Guilbaud
Oral presentation
New psychoactive substances tested by Energy Control, a community-based service of drug-checking and harm-reduction in Spain
10:50
to
12:20
Central square 3 (C3)
Adrià Quesada
Oral presentation
5. Drug use among non-binary persons in Europe: findings from a web survey
10:50
to
12:20
Networking zone 3 (N3)
Cristiana Vale Pires
Oral presentation
1. What is gender and why it is necessary to incorporate a gender perspective in the drug field? Evolution of key theoretical concepts in the area of gender and trends influencing the drug field
10:50
to
12:20
Networking zone 3 (N3)
Analia Torres
Oral presentation
1. How to reduce drug-related crimes
10:50
to
12:20
Central square 2 (C2)
Jorge Quintas
Oral presentation
2. 20 years of Portuguese drug policy: developments and current challenges
10:50
to
12:20
Central square 2 (C2)
Ximene Rêgo
Oral presentation
4. Drug consumption rooms in Lisbon: lessons learned
10:50
to
12:20
Central square 2 (C2)
Adriana Curado
Oral presentation
5. A strategy for all drug uses
10:50
to
12:20
Central square 2 (C2)
Maria Carmo Carvalho
Oral presentation
Factors associated with mortality in The Norwegian Offender Mental Health and Addiction (NorMA)- cohort
10:50
to
12:20
Central square 1 (C1)
Torill Tverborgvik
Oral presentation
All cause and cause specific mortality among individuals imprisoned for driving under the influence of alcohol and drugs in Norway (2000-2016)
10:50
to
12:20
Central square 1 (C1)
Ragnhild Jamt
Oral presentation
The Impact of Co-Occurring Mental Health Problems on Referral to and Initiation of Treatment Among Youth Under Probation Supervision
10:50
to
12:20
Central square 1 (C1)
Steven Belenko
Oral presentation
(Ex-)inmates' substance use: a needs assessment based on semi-structured interviews
10:50
to
12:20
Central square 1 (C1)
Nicky Dirkx
Oral presentation
Prevalence of heroin drug use before and during imprisonment in Europe: results from a comprehensive literature review and analysis of prevalence data in six European countries
10:50
to
12:20
Central square 1 (C1)
Sara Mazzilli
Oral presentation
3. Harm Reduction and Public Health: The place of 'subjugated knowledges'
10:50
to
12:20
Central square 2 (C2)
Daniel Martins
Oral presentation
PnP/CHEMSEX a means of surviving post-migration
10:50
to
12:20
Knowledge market 4 (K4)
Alexandre Brulotte
Oral presentation
Don’t cure, but care': affirmative intervention amongst men of sexual and gender diversity in the context of chemsex
10:50
to
12:20
Knowledge market 4 (K4)
Yannick Gaudette
Oral presentation
Identity matters in understanding gay and bisexual men's injecting drug use: a grounded theory study
10:50
to
12:20
Knowledge market 4 (K4)
Sophia Elvira Schroeder
Oral presentation
Interpersonal needs of gay, bisexual, and other msm who practice sexualized substance use: a critical component in treating substance use disorders among sexual minorities
10:50
to
12:20
Knowledge market 4 (K4)
Joseph De Piano
Oral presentation
The needs of professionals working on sexualized substance use and its implications for health and social services
10:50
to
12:20
Knowledge market 4 (K4)
Jorge Flores-Aranda
Oral presentation
1. An insight into alcohol, tobacco, drug, gambling and gaming in the Mediterranean Region: socioeconomic, policy context and patterns of use among adolescents
10:50
to
12:20
Networking zone 4 (N4)
Elisa Benedetti
Oral presentation
2. Gaming, gambling and social media use among Egyptian adolescents
10:50
to
12:20
Networking zone 4 (N4)
Nermin Shaker
Oral presentation
3. Adolescent substance use and risk behaviours in Morocco: results and indications for prevention
10:50
to
12:20
Networking zone 4 (N4)
Jallal Toufiq
Oral presentation
4. Gender differences and trends in substance use among Tunisian adolescent students
10:50
to
12:20
Networking zone 4 (N4)
Hajer Aounallah-Skhiri
Discussion
Recent developments in the gender field: the EIGE’s perspective
10:50
to
12:20
Networking zone 3 (N3)
13:20
Oral presentation
5. Harm reduction interventions and viral hepatitis elimination in prison: models of care and barriers for implementation
13:20
to
14:50
Main stage
Lara Tavoschi
Oral presentation
4. Impact, role, and prevalence of medication assisted treatment (MAT) for opioid users in European prisons
13:20
to
14:50
Main stage
Heino Stöver
Oral presentation
1. Provision of harm reduction interventions in European prisons: short overview of available services
13:20
to
14:50
Main stage
Linda Montanari
Oral presentation
2. Hepatitis C and HIV associated risk factors among people in prison in Latvia, Lithuania, Portugal, Spain: informing interventions to prevent communicable diseases in prison setting
13:20
to
14:50
Main stage
Laura Isajeva
Oral presentation
3. The international guidance on harm reduction interventions in prisons
13:20
to
14:50
Main stage
Ehab Salah
Oral presentation
Substance-related Consequences, Dependence and Substance Use Disorder: Promising new model taking clinical and statistical points of view into consideration
13:20
to
14:50
Central square 1 (C1)
Rosalie Genois
Oral presentation
Emerging Issues in the Management of Conflict of Interest
13:20
to
14:50
Central square 1 (C1)
Matej Košir
e-poster
Novel Psychoactive Substances (NPS) related health responses implemented in Europe through the lens of an intersectional risk environment approach
13:20
to
14:50
Networking zone 1 (N1)
Jessica Neicun
Oral presentation
Reproducibility and translation in addiction research
13:20
to
14:50
Central square 1 (C1)
Rainer Spanagel
e-poster
Four-year long wastewater-based monitoring of illicit drug consumption pilot project in Switzerland
13:20
to
14:50
Networking zone 2 (N2)
Livia Andrani
Oral presentation
3. Navigating an emergency response and collective action on the fentanyl frontlines: An ethnographic study of overdose prevention site implementation in Vancouver, Canada’s Downtown Eastside
13:20
to
14:50
Central square 2 (C2)
Ryan McNeil
e-poster
How are profiles of substance use linked to social function in the following seven years?
13:20
to
14:50
Networking zone 2 (N2)
Sidsel Karsberg
Oral presentation
1. Drug consumption rooms: welfare state and social acceptance in France
13:20
to
14:50
Central square 2 (C2)
Marie Jauffret-Roustide
e-poster
A systematic review of self-report and behavioural measures of the Addiction Neuroclinical Assessment constructs of incentive salience and negative emotionality, in adults who use psychoactive drugs.
13:20
to
14:50
Networking zone 2 (N2)
Maria Bravo Aguilera
Oral presentation
2. Drug consumption rooms in Denmark: attitudes and experiences from local residents
13:20
to
14:50
Central square 2 (C2)
Esben Houborg
e-poster
Changes in substance use during the COVID-19 pandemic: Longitudinal analysis of risk behavior and mental health of MSM using HIV pre-exposure prophylaxis
13:20
to
14:50
Networking zone 2 (N2)
Babette Lea Winter
e-poster
Alcohol Consumption during a Pandemic Lockdown Period and Change in Alcohol Consumption Related to Worries and Pandemic Measures
13:20
to
14:50
Networking zone 1 (N1)
Silvia Eiken Alpers
Oral presentation
Prevention and Treatment of hazardous Substance Use among Refugees: Perspectives from Germany
13:20
to
14:50
Central square 3 (C3)
Marion Laging
e-poster
Non-prescribed buprenorphine and reduction in illicit opioids use among individuals with opioid use disorder: a longitudinal study
13:20
to
14:50
Networking zone 2 (N2)
Raminta Daniulaityte
e-poster
Gender differences in HIV prevalence and all-cause mortality among people who inject drugs (PWID) in Estonia.
13:20
to
14:50
Networking zone 1 (N1)
Maris Salekesin
Oral presentation
Psychosocial functions of drug using and selling among young persons in Malmö who came to Sweden as unaccompanied refugee minors
13:20
to
14:50
Central square 3 (C3)
Anke Stallwitz
e-poster
Sexualized substance use, consumption motives and risk factors for relapse of addiction patients. Results of a cross-sectional study in addiction treatment facilities in Germany.
13:20
to
14:50
Networking zone 2 (N2)
Daniel Deimel
e-poster
Interaction between Alcohol Use Disorder, APOE4 and Cognitive Decline in patients undergoing an alcohol detoxification program
13:20
to
14:50
Networking zone 1 (N1)
Laura Orio
Oral presentation
Re-visioning from risk and safety to survival and wellness; behaviours among people who use methamphetamine with opioids in British Columbia, Canada
13:20
to
14:50
Central square 3 (C3)
Jessica Xavier
e-poster
How hair keeps track: Associations between hair concentrations of psychoactive substances and steroid hormones in a large cohort sample of young adults in Switzerland
13:20
to
14:50
Networking zone 2 (N2)
Lydia Johnson-Ferguson
e-poster
Functional Connectivity in a Triple-Network Saliency Model is Associated with Real-Life Self-Control
13:20
to
14:50
Networking zone 1 (N1)
Klaus-Martin Krönke
Oral presentation
Indigenous Peoples experiences with overdose and response in Vancouver, Canada's Downtown Eastside
13:20
to
14:50
Central square 3 (C3)
Jennifer Lavalley
Oral presentation
Language and concepts in alcohol use disorder: how framing affects stigma and recovery
13:20
to
14:50
Central square 1 (C1)
James Morris
e-poster
Lifestyle risk factors and racial and ethnic inequality in mortality: Decomposing differential exposure and vulnerability in the United States
13:20
to
14:50
Networking zone 1 (N1)
Klajdi Puka
Oral presentation
Watch out for the boogieman': multiple stigma and recovery experiences of ethnic minorities with substance use problems
13:20
to
14:50
Central square 3 (C3)
Aline Pouille
Oral presentation
Drinking patterns across Europe. Do beverage preferences matter?
13:20
to
14:50
Central square 1 (C1)
Janusz Sieroslawski
e-poster
Acceptance-based, intersectional stigma coping intervention for people with HIV who inject drugs – an RCT in St. Petersburg, Russia
13:20
to
14:50
Networking zone 1 (N1)
Karsten Lunze
Oral presentation
3. Amidst the most vulnerable voices: women and migrants in homeless situation with Alcohol UseDisorders (AUD)
13:20
to
14:50
Knowledge market 4 (K4)
Màrio Santos
Oral presentation
1. A novel way of enhancing adherence to acamprosate for alcohol dependence: The Alcohol Dependence and Adherence to Medicine (ADAM) trial
13:20
to
14:50
Networking zone 3 (N3)
Thomas Phillips
Oral presentation
5. All we can do - Emergency Shelter' staff positioning regarding alcohol related problems in thecontext of a new harm reduction intervention
13:20
to
14:50
Knowledge market 4 (K4)
Joana Tavares
Oral presentation
2. Effectiveness and cost-effectiveness of face-to-face and electronic brief interventions versus screening alone to reduce alcohol consumption among high-risk adolescents presenting to Emergency Departments: three-arm pragmatic randomised trial
13:20
to
14:50
Networking zone 3 (N3)
Paolo Deluca
Oral presentation
3. Alcohol Assertive Outreach Treatment randomised controlled trial: a mixed methods economic evaluation
13:20
to
14:50
Networking zone 3 (N3)
Amy Wolstenholme
Discussion
Lessons for future clinical research trials and clinical practice
13:20
to
14:50
Networking zone 3 (N3)
Karl Mann
Oral presentation
2. The experience of persons in homeless situation with alcohol related problems regarding a pharmacological harm reduction initiative
13:20
to
14:50
Knowledge market 4 (K4)
Raquel Medinas
Oral presentation
4. The role of those without a role - The perspective of non-clinical professionals in emergencyshelters on how to manage alcohol use disorder - police, security agents and cleaning staff
13:20
to
14:50
Knowledge market 4 (K4)
Ricardo Fuertes
Discussion
Prison health in Europe
13:20
to
14:50
Main stage
Fadi Meroueh,
Filipa Alves da Costa
Oral presentation
1. Individuals with lived experience of homelessness and alcohol use disorders - insights from the PLACE study
13:20
to
14:50
Knowledge market 4 (K4)
Ana Neto
Previous track
View all tracks
